In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients

Archives of Pharmacal Research

Volumn 31, Issue 3, 2008, Pages 406-413

  Ren, Shan ^a   Park, Mi Jin ^a   Kim, Aera ^a   Lee, Beom Jin ^a  

^a Kangwon National University   (South Korea)

Author keywords

Human liver microsomes; Metabolic stability; Pharmaceutical excipients; Rabeprazole; Thioether form

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; BUFFER; EXCIPIENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RABEPRAZOLE THIOETHER; RABEPRAZOLE-THIOETHER; SULFIDE; WATER;

ARTICLE; BIOLOGICAL MODEL; BIOTRANSFORMATION; CHEMISTRY; DRUG FORMULATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; KINETICS; LIVER MICROSOME; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PHARMACEUTICS; REPRODUCIBILITY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BIOTRANSFORMATION; BUFFERS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HUMANS; KINETICS; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PROTON PUMP INHIBITORS; REPRODUCIBILITY OF RESULTS; SULFIDES; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 46249095516     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1171-z     Document Type: Article

References (20)

1. Bravo Gonzalez, R. C., Huwyler, J., Boess, F., Walter, I., and Bittner, B., In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam. Biopharm. Drug Dispos., 25, 37-49 (2004).
2. Carswell, C. and Goa, K., Rabeprazole: An update of its use in acid-related disorders. Drugs, 61, 2327-2356 (2001).
3. da Silva, M. E. and Meirelles, N. C., Interaction of non-ionic surfactants with hepatic CYP in Prochilodus scrofa. Toxicol. In Vitro, 18, 859-867 (2004).
4. El-Gindy, A., El-Yazby, F., and Maher, M. M., Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products. J. Pharm. Biomed. Anal., 31, 229-242 (2003).
5. Fuhr, U. and Jetter, A., Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie, 57, 595-601 (2002).
6. Ishizaki, T. and Horai, Y., Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol. Ther., 13, 27-36 (1999).
7. Johnson, B. M., Charman, W. N., and Porter, C. J. H., An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm Sci., 4, Article 40 (2002).
8. Kassahun, K., McIntosh, I. S., Shou, M., Walsh, D. J., Rodeheffer, C., Slaughter, D. E., Geer, L. A., Halpin, R. A., Agrawal, N., and Rodrigues, A. D., Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab. Dispos., 29, 813-820 (2001).
9. Kowalczyk, I., Hawes, E. M., and McKay, G., Stability and enzymatic hydrolysis of quaternary ammonium-linked glucuronide metabolites of drugs with an aliphatic tertiary amine-implications for analysis. J. Pharm. Biomed. Anal., 22, 803-811 (2000).
10. McGinnity, D. F. and Riley, R. J., Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem. Soc. Trans., 29, 135-139 (2001).
11. Meyer, U. A., Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J. Biol. Med., 69, 203-209 (1996).
12. Michaelis, L. and Menten, M. L., Die kinetik der invertinwirkung. Biochem. Z., 49, 333-369 (1993).
13. Mountfield, R. J., Senepin, S., Schleimer, M., Walter, I., and Bittner, B., Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int. J. Pharm., 211, 89-92 (2000).
14. Ren, S., Park, M.-J., Sah, H., and Lee, B.-J., Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium. Int. J. Pharm., [In Press] (2007).
15. Vanden Branden, M., Ring, B. J., Binkley, S. N., and Wrighton, S. A., Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton inhibitor. Pharmacogenetics, 6, 81-91 (1996).
16. Villalobos-Hernandez, J. R. and Villafuerte-Robles, L., Effect of carrier excipient and processing on stability of indorenate hydrochloride/excipient mixtures. Pharm. Dev. Technol., 6, 551-561 (2001).
17. Watkins, P. B., Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol. Clin. North. Am., 21, 511-526 (1992).
18. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., and Guzelian, P. S., Identification of glucocorticoid-Inducible cytochrome P-450 in the intestinal mucosa of rats and man. J. Clin. Invest., 80, 1029-1036 (1987).
19. Yang, P. and Macdonald, F., Solution stability of factor Xa inhibitors as a function of pH. Drug Dev. Ind. Pharm., 30, 967-973 (2004).
20. Yasuda, S., Horai, Y., Tomono, Y., Nakai, H., Yamato, C., Manabe, K., Kobayashi, K., Chiba, K., and Ishizaki, T., Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin. Pharmacol. Ther., 58, 143-154 (1995).